Olipudase alfa: Phase I/II started

Sanofi’s Genzyme Corp. unit began an open-label, dose-escalation, international Phase I/II trial to evaluate IV olipudase alfa every 2 weeks for 52 weeks in 12 pediatric patients with non-neurologica...